drugset / Trial / NCT07506512

Optimal Time Interval Between Mifepristone and Misoprostol Administration for Early Pregnancy Loss

NCT07506512

Phase 3 Not yet recruiting 1000 enrolled University of Pennsylvania
NaSingle-groupOpen-labelTreatment

Summary

A prospective cohort study to explore the optimal time interval between mifepristone and misoprostol administration for medical management of early pregnancy loss. Participants will be followed to assess treatment success, satisfaction, and side effects.

Timeline

Start
2026-07
Primary completion
2031-07
Completion
2031-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mifepristone Small molecule 200 mg Oral
Subject Misoprostol Other / unclassified 800 mg Other